Comparison of an ID NOW COVID-19 Assay Used at the Point of Care to Laboratory-Based Nucleic Acid Amplification Tests

Payne, D. J.; Williams, Channyn; Jacob, Justin; Chastain-Potts, Shelby; Adjei, Michael D.; Taye, Bineyam; Montalvo, S. Medina; Short, Liz; Tran, Anthony

doi:10.1128/jcm.00413-23

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of the test line signal is directly proportional to the concentration, and it is even possible to obtain a quantitative value using an electronic sensor device [6] . Many studies reported the use of nucleic acids instead of proteins in lateral flow assays [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] . However, there was no significant progress or widespread application on the commercial side.…”

Section: Introductionmentioning

confidence: 99%

Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Akalın,

Yazgan-Karataş

2023

MethodsX

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Akalın,

Yazgan-Karataş

2023

MethodsX

View full text Add to dashboard Cite

Implementation of point-of-care molecular testing for respiratory viruses in congregate living settings

Tan,

Chan,

Ofner

et al. 2024

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

Objective: To implement and evaluate a point-of-care (POC) molecular testing platform for respiratory viruses in congregate living settings (CLS). Design: Prospective quality improvement study. Setting: Seven CLS, including three nursing homes and four independent-living facilities. Participants: Residents of CLS. Methods: A POC platform for COVID-19, influenza A and B, and respiratory syncytial virus was implemented at participating CLS from December 1, 2022 to April 15, 2023. Residents with respiratory symptoms underwent paired testing, with respiratory specimens tested first with the POC platform and then delivered to an off-site laboratory for multiplex respiratory virus panel (MRVP) polymerase chain reaction (PCR) as per standard protocol. Turn-around time and diagnostic accuracy of the POC platform were compared against MRVP PCR. In an exploratory analysis, time to outbreak declaration among participating CLS was compared against a convenience sample of 19 CLS that did not use the POC platform. Results: A total of 290 specimens that underwent paired testing were included. Turn-around time to result was significantly shorter with the POC platform compared to MRVP PCR, with median difference of 36.2 hours (interquartile range 21.8–46.4 hours). The POC platform had excellent diagnostic accuracy compared to MRVP PCR, with area under the curve statistic of .96. Time to outbreak declaration was shorter in CLS that used the POC platform compared to CLS that did not. Conclusion: Rapid POC testing platforms for respiratory viruses can be implemented in CLS, with high diagnostic accuracy, expedited turn-around times, and shorter time to outbreak declaration.

show abstract

Comparison of an ID NOW COVID-19 Assay Used at the Point of Care to Laboratory-Based Nucleic Acid Amplification Tests

Abstract: The emergence of a novel coronavirus, namely, SARS-CoV-2, necessitated the use of rapid, accurate diagnostics to quickly diagnose COVID-19. This need has increased with the emergence of new variants and continued waves of COVID-19 cases.

Cited by 2 publications

References 22 publications

Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Implementation of point-of-care molecular testing for respiratory viruses in congregate living settings

Contact Info

Product

Resources

About